Scientific research now confirms that anxiety and insomnia can be caused by irregularities in the brain’s neurochemicals. Through our patented, frequency-related, advanced waveform that interacts with the deep centers of the midbrain, our Nexalin device supports the normalization of these chemicals. And best of all, without medication.

Mar 6, 2024 · Nexalin utilizes bioelectronic medical technology to treat mental health issues without the need for drugs or psychotherapy. Nexalin believes the 15 milliamp medical device can penetrate structures deep in the mid-brain that are associated with mental health disorders.

Dec 18, 2023 · Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders.

Apr 1, 2024 · Newly announced findings from a placebo-controlled trial showed that treatment with Nexalin’s Gen-2 transcranial electrical stimulation (tES) device resulted in significant reductions in delta-band activity and abnormal gamma-band activity in veterans with mild traumatic brain injury (mTBI).

The published results of the study concluded that repeated treatment with Nexalin’s neurostimulation device suggests an acute effect in reducing depressive symptoms in patients with TRD. In...

Mar 6, 2024 · Nexalin Technology, Inc. Clinical study demonstrated clinically meaningful and statistically significant improvements in key sleep parameters, compared to adult patients treated with placebo

HOUSTON, TEXAS, March 28, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the positive results of a clinical study evaluating...

Oct 18, 2024 · Nexalin has unveiled mixed results from a clinical trial evaluating its deep intracranial frequency stimulation (DIFS) technology in patients with mild Alzheimer’s disease, with the primary endpoint missed but positive data reported in secondary endpoints.

Jan 23, 2024 · Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No. 11,872,397 relating to the Company’s non-invasive, frequency-based deep brain stimulation device.

Oct 16, 2023 · Study reveals that Nexalin’s non-invasive, deep frequency stimulation medical device can directly stimulate the deep intracranial nuclei, an area of the brain frequently associated with...